New Gold has transitioned from promise to delivery, showing strong operational execution, margin expansion, and robust FCF in Q2 2025. Valuation remains deeply discounted versus peers despite superior ...
Medtronic boasts strong free cash flow, stable dividends, and innovation focus, but faces macro headwinds, high debt, and competitive pressures. Recent strategic portfolio moves, including spin-offs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback